Bendamustine Hydrochloride Injection, Powder, Lyophilized, For Solution
Product Images NDC 55150-392

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bendamustine Hydrochloride (NDC 55150-392). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Eugia Us Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Progression-free Survival (Bendamustine Fig1)

A line graph titled 'Progression-Free Survival' showing survival distribution function on the y-axis and progression-free survival in months on the x-axis. Two treatment groups are compared: Bendamustine Hydrochloride represented by a solid line, and Chlorambucil represented by a dashed line.*

FDA Label Image

Package Label-principal Display Panel-25 mg Per Vial (Container Label)

Label for Bendamustine Hydrochloride for Injection, USP 25 mg per vial, lyophilized powder for intravenous infusion. The label indicates reconstitution and dilution are required and describes the vial as sterile and single-dose. Manufactured by Eugia US LLC, with storage and administration instructions included.*

FDA Label Image

Package Label-principal Display Panel-25 mg Per Vial (Container-Carton (1 Vial))

Bendamustine Hydrochloride for Injection, USP 25 mg per Vial lyophilized powder for intravenous infusion. The label states it requires reconstitution and dilution before use, with instructions to retain in carton until use and discard unused portion. Distributed by Eugia US LLC, the label includes handling precautions as a cytotoxic agent and storage conditions. Made in India.*

FDA Label Image

Package Label-principal Display Panel-100 mg Per Vial (Container Label)

BENDAMUSTINE HYDROCHLORIDE 100 mg per vial injection powder label for intravenous use. The vial is single-dose and sterile, with a cytotoxic agent warning. The label includes reconstitution instructions and storage conditions, noting the product is made for Eugia US LLC and contains 100 mg bendamustine HCl and 170 mg mannitol.*

FDA Label Image

Package Label-principal Display Panel-100 mg Per Vial (Container-Carton (1 Vial))

Packaging label for Bendamustine Hydrochloride for Injection, USP, 100 mg per vial, lyophilized powder for solution. The label states it is for intravenous infusion only and requires reconstitution and dilution. Distributed by Eugia US LLC, the vial is a sterile single-dose. Storage and handling instructions, including use of gloves and safety glasses, are also noted.*

FDA Label Image

Chemical Structure (Bendamustine Str)

Chemical structure diagram of bendamustine hydrochloride showing its molecular components, including chloroethyl groups, a benzimidazole ring system, and a carboxylic acid group with associated hydrochloride and water molecules.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.